| Bioactivity | EGFR-IN-11 is a fourth-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) with an IC50 of 18 nM for triple mutant EGFRL858R/T790M/C797S. EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1[1]. | ||||||||||||
| Invitro | EGFR-IN-11 (Compound D9; 0.0001-10 µM; 72 hours) shows significantly potent anti-proliferation against HCC827 and H1975 cell lines with IC50s of 0.88 nM and 0.20 µM, respectively[1]. EGFR-IN-11 (0.01-1.00 µM for HCC827 cells; 0.1-10.00 µM for H1975 and A549 cells; 8 hours) suppresses EGFR phosphorylation in a concentration-dependent manner in the HCC827, H1975 and A549 cell line[1]. EGFR-IN-11 (1 µM; 24 h) potently induces the apoptosis of HCC827 cells.[1]EGFR-IN-11 (1 µM; 24 h) induces cell cycle arrests in HCC827 cell[1]. Cell Proliferation Assay[1] Cell Line: | ||||||||||||
| Name | EGFR-IN-11 | ||||||||||||
| CAS | 2463200-44-2 | ||||||||||||
| Formula | C29H35N9O2S | ||||||||||||
| Molar Mass | 573.71 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
EGFR-IN-11
CAS: 2463200-44-2 F: C29H35N9O2S W: 573.71
EGFR-IN-11 is a fourth-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) with an IC50 of 18 nM for triple mutant EGFR
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.